Insider filing · NAMS
NewAmsterdam Pharma Company N.V.
NAMS · Healthcare · 45 filings in 24 months
ticker →
Forbion IV Management B.V. sold $4.9M of NewAmsterdam Pharma (NAMS)
Executed Dec 12 2024, disclosed Dec 16 2024, 4 days later.
Value, as filed
$4.9M
191,762 sh across 3 lots
Executed
Dec 12 2024
the trade date, as filed
Disclosed
Dec 16 2024
4 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
FV
Forbion IV Management B.V.
10% owner
profile →
Forbion IV Management B.V. (10% owner) filed 3 Form 4 reports as a reporting entity in the past 24 months (0 purchases, 3 sales, 1 filed past the two-business-day deadline), most often in NewAmsterdam Pharma Company N.V. (NAMS). The largest single filing was $4.9M of NAMS (191,762 sh across 3 lots, as filed), executed Dec 12 2024.
The name
NAMSHealthcare · NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with ca…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Forbion IV Management B.V. in NAMS
NAMSSALE
NewAmsterdam Pharma Company N.V.
$2.3M91,068 sh across 4 lots
Exec Dec 20 2024
Filed Dec 26 2024 · 5:30 PM ET † NAMSSALE NewAmsterdam Pharma Company N.V. $3.0M
114,384 sh across 2 lots
Exec Dec 17 2024
Filed Dec 18 2024 · 5:30 PM ET